Financhill
Buy
54

RAFA Quote, Financials, Valuation and Earnings

Last price:
$0.0900
Seasonality move :
64.19%
Day range:
$0.0751 - $0.0991
52-week range:
$0.0330 - $0.1790
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
23.9K
Avg. volume:
41.7K
1-year change:
25%
Market cap:
$7.5M
Revenue:
--
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
RAFA
Rafarma Pharmaceuticals
-- -- -- -- --
ATNM
Actinium Pharmaceuticals
-- -$0.35 -100% -7.24% $5.00
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.47 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
RAFA
Rafarma Pharmaceuticals
$0.0900 -- $7.5M -- $0.00 0% --
ATNM
Actinium Pharmaceuticals
$1.57 $5.00 $49M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.69 $0.85 $4M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.60 -- $25.7M -- $0.00 0% --
OGEN
Oragenics
$1.41 $1.00 $1M -- $0.00 0% 0.45x
TOVX
Theriva Biologics
$0.50 $7.00 $4.1M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
RAFA
Rafarma Pharmaceuticals
-- -3.026 -- --
ATNM
Actinium Pharmaceuticals
-- -3.037 -- 9.03x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
NNVC
Nanoviricides
-- -0.318 -- --
OGEN
Oragenics
-- 0.068 -- --
TOVX
Theriva Biologics
-- -3.388 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
RAFA
Rafarma Pharmaceuticals
-- -- -- -- -- --
ATNM
Actinium Pharmaceuticals
-- -$16.6M -95.08% -95.08% -12769.14% -$7.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Rafarma Pharmaceuticals vs. Competitors

  • Which has Higher Returns RAFA or ATNM?

    Actinium Pharmaceuticals has a net margin of -- compared to Rafarma Pharmaceuticals's net margin of -11511.11%. Rafarma Pharmaceuticals's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    RAFA
    Rafarma Pharmaceuticals
    -- -- --
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
  • What do Analysts Say About RAFA or ATNM?

    Rafarma Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 218.47%. Given that Actinium Pharmaceuticals has higher upside potential than Rafarma Pharmaceuticals, analysts believe Actinium Pharmaceuticals is more attractive than Rafarma Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RAFA
    Rafarma Pharmaceuticals
    0 0 0
    ATNM
    Actinium Pharmaceuticals
    2 1 0
  • Is RAFA or ATNM More Risky?

    Rafarma Pharmaceuticals has a beta of 0.927, which suggesting that the stock is 7.253% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.325, suggesting its less volatile than the S&P 500 by 132.486%.

  • Which is a Better Dividend Stock RAFA or ATNM?

    Rafarma Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RAFA or ATNM?

    Rafarma Pharmaceuticals quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. Rafarma Pharmaceuticals's net income of -- is lower than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Rafarma Pharmaceuticals's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RAFA
    Rafarma Pharmaceuticals
    -- -- -- --
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
  • Which has Higher Returns RAFA or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Rafarma Pharmaceuticals's net margin of -49.65%. Rafarma Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    RAFA
    Rafarma Pharmaceuticals
    -- -- --
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About RAFA or NBY?

    Rafarma Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 23.19%. Given that NovaBay Pharmaceuticals has higher upside potential than Rafarma Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Rafarma Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RAFA
    Rafarma Pharmaceuticals
    0 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is RAFA or NBY More Risky?

    Rafarma Pharmaceuticals has a beta of 0.927, which suggesting that the stock is 7.253% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock RAFA or NBY?

    Rafarma Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RAFA or NBY?

    Rafarma Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Rafarma Pharmaceuticals's net income of -- is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Rafarma Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RAFA
    Rafarma Pharmaceuticals
    -- -- -- --
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns RAFA or NNVC?

    Nanoviricides has a net margin of -- compared to Rafarma Pharmaceuticals's net margin of --. Rafarma Pharmaceuticals's return on equity of -- beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RAFA
    Rafarma Pharmaceuticals
    -- -- --
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About RAFA or NNVC?

    Rafarma Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 306.25%. Given that Nanoviricides has higher upside potential than Rafarma Pharmaceuticals, analysts believe Nanoviricides is more attractive than Rafarma Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RAFA
    Rafarma Pharmaceuticals
    0 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is RAFA or NNVC More Risky?

    Rafarma Pharmaceuticals has a beta of 0.927, which suggesting that the stock is 7.253% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.

  • Which is a Better Dividend Stock RAFA or NNVC?

    Rafarma Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RAFA or NNVC?

    Rafarma Pharmaceuticals quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Rafarma Pharmaceuticals's net income of -- is lower than Nanoviricides's net income of -$2.2M. Notably, Rafarma Pharmaceuticals's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RAFA
    Rafarma Pharmaceuticals
    -- -- -- --
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns RAFA or OGEN?

    Oragenics has a net margin of -- compared to Rafarma Pharmaceuticals's net margin of --. Rafarma Pharmaceuticals's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RAFA
    Rafarma Pharmaceuticals
    -- -- --
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About RAFA or OGEN?

    Rafarma Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2027.87%. Given that Oragenics has higher upside potential than Rafarma Pharmaceuticals, analysts believe Oragenics is more attractive than Rafarma Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RAFA
    Rafarma Pharmaceuticals
    0 0 0
    OGEN
    Oragenics
    0 1 0
  • Is RAFA or OGEN More Risky?

    Rafarma Pharmaceuticals has a beta of 0.927, which suggesting that the stock is 7.253% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock RAFA or OGEN?

    Rafarma Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RAFA or OGEN?

    Rafarma Pharmaceuticals quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Rafarma Pharmaceuticals's net income of -- is lower than Oragenics's net income of -$2.2M. Notably, Rafarma Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals is -- versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RAFA
    Rafarma Pharmaceuticals
    -- -- -- --
    OGEN
    Oragenics
    0.45x -- -- -$2.2M
  • Which has Higher Returns RAFA or TOVX?

    Theriva Biologics has a net margin of -- compared to Rafarma Pharmaceuticals's net margin of --. Rafarma Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RAFA
    Rafarma Pharmaceuticals
    -- -- --
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About RAFA or TOVX?

    Rafarma Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1308.45%. Given that Theriva Biologics has higher upside potential than Rafarma Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Rafarma Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RAFA
    Rafarma Pharmaceuticals
    0 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is RAFA or TOVX More Risky?

    Rafarma Pharmaceuticals has a beta of 0.927, which suggesting that the stock is 7.253% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock RAFA or TOVX?

    Rafarma Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RAFA or TOVX?

    Rafarma Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Rafarma Pharmaceuticals's net income of -- is lower than Theriva Biologics's net income of -$4.3M. Notably, Rafarma Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RAFA
    Rafarma Pharmaceuticals
    -- -- -- --
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Can SharkNinja Stock Go?
How High Can SharkNinja Stock Go?

If you know popular consumer appliance brands Shark and Ninja,…

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
77
VBTX alert for Jul 15

Veritex Holdings [VBTX] is down 3.26% over the past day.

Buy
72
MNPR alert for Jul 15

Monopar Therapeutics [MNPR] is down 8.6% over the past day.

Buy
56
NBIS alert for Jul 15

Nebius Group NV [NBIS] is up 2.98% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock